ABSTRACT
This chapter provides the validated targets and the drugs used for the treatment of the disease, the progressive neurodegeneration characteristics of Alzheimer’s disease (AD) concomitant to its pathophysiology, and approaches on the multi-target ligand design studies based on the neurodegenerative characteristics of the disease to summarize the approaches for alternative treatment options. AD falls under the category of neurodegenerative diseases. Statistics indicate that the number of current AD patients is around 50 million worldwide. AD-related dementia is quite different. In fact, AD is the most common form of dementia. Since the disease has a progressive neurodegenerative characteristic behind, the dementia associated with the disease must be treated. Some of the phase trials employing drug candidates purely designed to target one of the neurodegenerative mechanisms have provided promising results in terms of the prevention of toxic mechanisms.
